UBS analyst Eliana Merle raised the firm’s price target on BioMarin (BMRN) to $113 from $109 and keeps a Buy rating on the shares. BioMarin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback